D
55
-6
LEG
29
4
AKAM
56
-2
ETN
73
-2
HES
59
3
GOOG
63
2
CTAS
56
-5
VFC
57
4
SHW
71
-2
PAYX
53
-4
SLG
66
4
CHD
53
-3
HRL
38
2
NWL
32
-3
FRT
41
-2
VRTX
56
-4
WYNN
34
-3
PEP
50
-4
V
64
-4
RIG
35
-3
D
55
-6
LEG
29
4
AKAM
56
-2
ETN
73
-2
HES
59
3
GOOG
63
2
CTAS
56
-5
VFC
57
4
SHW
71
-2
PAYX
53
-4
SLG
66
4
CHD
53
-3
HRL
38
2
NWL
32
-3
FRT
41
-2
VRTX
56
-4
WYNN
34
-3
PEP
50
-4
V
64
-4
RIG
35
-3
Financhill
Back

Ascendis Pharma AS 10K Form

Sell
41

ASND
Ascendis Pharma AS

Last Price:
151.45
Seasonality Move:
6.54%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ASND News And Ratings

See the #1 stock for the next 7 days that we like better than ASND

ASND Financial Statistics

Sales & Book Value

Annual Sales: $288.75M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $-6.00
Price / Book: 0

Profitability

EPS (TTM): -9.34900
Net Income (TTM): $-530.29M
Gross Margin: $240.69M
Return on Equity: 0%
Return on Assets: -60.1%

Ascendis Pharma AS Earnings Forecast

Key Ascendis Pharma AS Financial Ratios

  • The Gross Profit Margin over the past 5 years for ASND is 83.36%.
  • The Selling, General & Administrative Expenses for ASND have been equal to 99.13% of Gross Profit Margin.
  • The Research & Development expenses have been 155.02% of Revenue.
  • The Interest Expense is -9.15% of Operating Income.
  • The Net Earning history of ASND is -180.51% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 4 years.

Ascendis Pharma AS Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ASND
CUSIP: 04351P
Website: ascendispharma.com

Debt

Debt-to-Equity Ratio: -2.09
Current Ratio: 0.74
Quick Ratio: 0.4

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ASND Technical Analysis vs Fundamental Analysis

Sell
41
Ascendis Pharma AS (ASND) is a Sell

Is Ascendis Pharma AS a Buy or a Sell?